open access

Vol 12, No 1 (2017)
Review Papers
Published online: 2016-09-13
Get Citation

Pentraxin 3 as an independent marker of coronary artery disease development, progression and prognosis

Monika Ewa Gil, Anna Lisowska, Włodzimierz Jerzy Musiał, Małgorzata Anna Knapp
DOI: 10.5603/FC.a2016.0071
·
Folia Cardiologica 2017;12(1):55-60.

open access

Vol 12, No 1 (2017)
Review Papers
Published online: 2016-09-13

Abstract

Pentraxin 3 (PTX3) is an acute phase protein that, likely to C-reactive protein (CRP), belongs to pentraxin superfamily. PTX3 is produced as a response to inflammatory mediators by several types of cells directly associated with atherosclerosis such as endothelial cells or macrophages. Thus PTX3 appears to be a specific indicator of localized inflammatory process. PTX3 reflects inflammatory status in cardiovascular diseases such as subclinical atherosclerosis, coronary artery disease, acute coronary syndromes (ACS) and heart failure. Association of PTX3 with cardiovascular risk factors suggests that it can be a promising marker of subclinical and symptomatic atherosclerosis. Previous research suggests that PTX3 may be a useful diagnostic marker of ACS. Furthermore, in patients after ACS or with heart failure it appears an independent prognostic factor.

Abstract

Pentraxin 3 (PTX3) is an acute phase protein that, likely to C-reactive protein (CRP), belongs to pentraxin superfamily. PTX3 is produced as a response to inflammatory mediators by several types of cells directly associated with atherosclerosis such as endothelial cells or macrophages. Thus PTX3 appears to be a specific indicator of localized inflammatory process. PTX3 reflects inflammatory status in cardiovascular diseases such as subclinical atherosclerosis, coronary artery disease, acute coronary syndromes (ACS) and heart failure. Association of PTX3 with cardiovascular risk factors suggests that it can be a promising marker of subclinical and symptomatic atherosclerosis. Previous research suggests that PTX3 may be a useful diagnostic marker of ACS. Furthermore, in patients after ACS or with heart failure it appears an independent prognostic factor.

Get Citation

Keywords

pentraxin 3, atherosclerosis, atherosclerotic plaque, cardiovascular risk factors, coronary artery disease, acute coronary syndromes, heart failure

About this article
Title

Pentraxin 3 as an independent marker of coronary artery disease development, progression and prognosis

Journal

Folia Cardiologica

Issue

Vol 12, No 1 (2017)

Pages

55-60

Published online

2016-09-13

DOI

10.5603/FC.a2016.0071

Bibliographic record

Folia Cardiologica 2017;12(1):55-60.

Keywords

pentraxin 3
atherosclerosis
atherosclerotic plaque
cardiovascular risk factors
coronary artery disease
acute coronary syndromes
heart failure

Authors

Monika Ewa Gil
Anna Lisowska
Włodzimierz Jerzy Musiał
Małgorzata Anna Knapp

References (40)
  1. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006; 45(5): 326–330.
  2. Breviario F, d'Aniello EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992; 267(31): 22190–22197.
  3. Han B, Mura M, Andrade CF, et al. TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol. 2005; 175(12): 8303–8311.
  4. Introna M, Alles VV, Castellamo M, et al. Cloning of mouse extrahepatic sites. Blood. 1996; 87(5): 1862–1872.
  5. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007; 204(4): 793–804.
  6. Garlanda C, Hirsch E, Bozza S, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002; 420(6912): 182–186.
  7. Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003; 33(2): 465–473.
  8. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102(6): 636–641.
  9. Latini R, Maggioni AP, Peri G, et al. Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110(16): 2349–2354.
  10. Tazaki R, Tanigawa J, Fujisaka T, et al. Plasma pentraxin 3 level is associated with plaque vulnerability assessed by optical coherence tomography in patients with coronary artery disease. Int Heart J. 2016; 57(1): 18–24.
  11. Jenny NS, Arnold AM, Kuller LH, et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009; 29(4): 594–599.
  12. Yano Y, Matsuda S, Hatakeyama K, et al. Plasma pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci. 2010; 65(5): 547–552.
  13. Ohbayashi H, Miyazawa C, Miyamoto K, et al. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb. 2009; 16(4): 490–500.
  14. Jylhävä J, Haarala A, Kähönen M, et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol. 2011; 164(2): 211–217.
  15. Zanetti M, Bosutti A, Ferreira C, et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009; 9(3): 243–248.
  16. Yamasaki K, Kurimura M, Kasai T, et al. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009; 47(4): 471–477.
  17. Rashtchizadeh N, Ghaffari M, Sede SA, et al. Associations of pentraxin 3 with presence and severity of coronary artery disease in type 2 diabetes patients. Turk J Biochem. 2015; 40(1): 37–43.
  18. Jenny NS, Blumenthal RS, Kronmal RA, et al. Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost. 2014; 12(6): 999–1005.
  19. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007; 27(1): 161–167.
  20. Dubin R, Li Y, Ix JH, et al. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012; 163(2): 274–279.
  21. Ogawa T, Kawano Y, Imamura T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring). 2010; 18(9): 1871–1874.
  22. Barazzoni R, Aleksova A, Carriere C, et al. Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome. Cardiovasc Diabetol. 2013; 12: 167.
  23. Tomandlova M, Jarkovsky J, Tomandl J, et al. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers. 2015; 2015: 159051.
  24. Koga S, Ikeda S, Yoshida T, et al. Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv. 2013; 6(9): 945–954.
  25. Vuković-Dejanović V, Bogavac-Stanojević N, Spasić S, et al. Association of serum pentraxin-3 and high-sensitivity C-reactive protein with the extent of coronary stenosis in patients undergoing coronary angiography. J Med Biochem. 2015; 34(4): 440–449.
  26. Liu H, Guan S, Fang W, et al. Associations between pentraxin 3 and severity of coronary artery disease. BMJ Open. 2015; 5(4): e007123.
  27. Klouche M, Peri G, Knabbe C, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004; 175(2): 221–228.
  28. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009; 120(8): 699–708.
  29. Camozzi M, Zacchigna S, Rusnati M, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2005; 25(9): 1837–1842.
  30. Brambilla M, Camera M, Colnago D, et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol. 2008; 28(5): 947–953.
  31. Santilli F, Guagnano MT, Innocenti P, et al. Pentraxin 3 and platelet activation in obese patients after gastric banding. Circ J. 2016; 80(2): 502–511.
  32. Kume N, Mitsuoka H, Hayashida K, et al. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol. 2011; 58(1): 38–45.
  33. Latini R, Gullestad L, Masson S, et al. Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012; 14(9): 992–999.
  34. Kimura S, Inagaki H, Haraguchi Go, et al. Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction. Circ J. 2014; 78(1): 159–169.
  35. Guo R, Li Y, Wen J, et al. Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology. 2014; 129(3): 178–188.
  36. Matsui S, Ishii J, Kitagawa F, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2010; 210(1): 220–225.
  37. Miyazaki T, Chiuve S, Sacks FM, et al. Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS One. 2014; 9(4): e94073.
  38. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008; 155(1): 75–81.
  39. Saygı S, Kırılmaz B, Tengiz İ, et al. Long pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting. Turk Kardiyol Dern Ars. 2012; 40(3): 205–212.
  40. Matsubara J, Sugiyama S, Nozaki T, et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc. 2014; 3(4).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl